Loading clinical trials...
Loading clinical trials...
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients
Conditions
Interventions
MP-376
Placebo
Locations
39
United States
Haleyville, Alabama, United States
Hueytown, Alabama, United States
Mobile, Alabama, United States
Montgomery, Alabama, United States
Glendale, Arizona, United States
Phoenix, Arizona, United States
Start Date
October 1, 2008
Primary Completion Date
January 1, 2010
Completion Date
April 1, 2010
Last Updated
December 27, 2024
NCT05746039
NCT07509606
NCT07477600
NCT05878769
NCT06717659
NCT07274631
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions